Search research articles
Contact Us
Filters
Showing results (11-20 of 201) with videos related to
Page
of 21
Sort By:
Clinical Chemistry and Laboratory Medicine
|
April 17, 2012
Evaluation of the interference by homogentisic acid and other organic acids on the enzymatic and Jaffé method creatinine assay
Steven Pauwels, David Cassiman, Pieter Vermeersch
Orphanet Journal of Rare Diseases
|
September 12, 2014
Reimbursement of orphan drugs in Belgium: what (else) matters?
Eline Picavet, David Cassiman, Steven Simoens
Health Policy (Amsterdam, Netherlands)
|
September 20, 2012
Evaluating and improving orphan drug regulations in Europe: a Delphi policy study
Eline Picavet, David Cassiman, Steven Simoens
Journal of Hepatology
|
March 8, 2024
Rare monogenic causes of steatotic liver disease masquerading as MASLD
Martijn C G J Brouwers, David Cassiman
Journal of Inherited Metabolic Disease
|
October 2, 2021
Patents vs patients 1-0: The case of chenodeoxycholic acid
Sarah Marie Briké, Wouter Meersseman, David Cassiman
Gastroenterology
|
September 1, 2014
Hepatitis with brown pigment in the liver
Hannah van Malenstein, Louis Libbrecht, David Cassiman
Molecular Genetics and Metabolism
|
April 22, 2019
Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases
Carlos R Ferreira, David Cassiman, Nenad Blau
Neurology
|
October 29, 2003
Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS
David Cassiman, Michiel Thomeer, Erik Verbeken, et al.
Orphanet Journal of Rare Diseases
|
April 29, 2014
Shining a light in the black box of orphan drug pricing
Eline Picavet, Thomas Morel, David Cassiman, et al.
Applied Health Economics and Health Policy
|
June 21, 2011
Drugs for rare diseases: influence of orphan designation status on price
Eline Picavet, Marc Dooms, David Cassiman, et al.
Page
of 21
Search research articles
Search
Showing results (11-20 of 201) with videos related to
Sort By:
Page
of 21
Clinical Chemistry and Laboratory Medicine
|
April 17, 2012
Evaluation of the interference by homogentisic acid and other organic acids on the enzymatic and Jaffé method creatinine assay
Steven Pauwels, David Cassiman, Pieter Vermeersch
Orphanet Journal of Rare Diseases
|
September 12, 2014
Reimbursement of orphan drugs in Belgium: what (else) matters?
Eline Picavet, David Cassiman, Steven Simoens
Health Policy (Amsterdam, Netherlands)
|
September 20, 2012
Evaluating and improving orphan drug regulations in Europe: a Delphi policy study
Eline Picavet, David Cassiman, Steven Simoens
Journal of Hepatology
|
March 8, 2024
Rare monogenic causes of steatotic liver disease masquerading as MASLD
Martijn C G J Brouwers, David Cassiman
Journal of Inherited Metabolic Disease
|
October 2, 2021
Patents vs patients 1-0: The case of chenodeoxycholic acid
Sarah Marie Briké, Wouter Meersseman, David Cassiman
Gastroenterology
|
September 1, 2014
Hepatitis with brown pigment in the liver
Hannah van Malenstein, Louis Libbrecht, David Cassiman
Molecular Genetics and Metabolism
|
April 22, 2019
Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases
Carlos R Ferreira, David Cassiman, Nenad Blau
Neurology
|
October 29, 2003
Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS
David Cassiman, Michiel Thomeer, Erik Verbeken, et al.
Orphanet Journal of Rare Diseases
|
April 29, 2014
Shining a light in the black box of orphan drug pricing
Eline Picavet, Thomas Morel, David Cassiman, et al.
Applied Health Economics and Health Policy
|
June 21, 2011
Drugs for rare diseases: influence of orphan designation status on price
Eline Picavet, Marc Dooms, David Cassiman, et al.
Page
of 21